According to the company, the results provide a view into how 600 clinical trial sites, sponsors, and CROs from across the globe are responding to emerging trends for patient engagement.
The survey results indicate that sites, sponsors and CROs are increasingly turning to digital tools to engage patients throughout their clinical trial journey and that these technologies should be comprehensive versus several disparate technologies.
The consensus globally indicates that 85% of sponsors and CROs agree that it would be beneficial to have one unified solution to deliver their entire patient engagement program.
Additionally, 90% of sites strongly believe it would be valuable to have a singular digital access point for patients to access their study information, such as reimbursements, transportation, appointment reminders and more.
More than 45% of sites also agree that sponsors and CROs should provide the technology resources for studies.
Jim Murphy, CEO of Greenphire, told Outsourcing Phama: “The Economist has reported that drugs developed using patient-centric designs are 20% more likely to be launched than those without, irrespective of therapeutic area.”
“This has most certainly been a driver for the increased adoption of participant convenience services within the clinical trial industry, having recognized that 80% of delays in clinical trial timelines are attributed to poor recruitment and retention.
“Despite increasing protocol complexity, sponsors and CROs have prioritized keeping participants engaged, to ensure treatments get to those who need them most as quickly as possible. That's why we conducted this survey – to hear directly from sites, sponsors and CROs on the latest challenges and trends across the clinical trial landscape.”
Murphy added that this survey provides Greenphire will ‘valuable insights’ into how the company can help streamline administrative processes and provide better logistics coordination and quicker reimbursements.
“Through unified technology, from study start up to finish, our goal is to make clinical trial participation a more effective, efficient, and enjoyable process for all involved parties while still meeting the highest standards of data integrity,” he concluded.
